The aim of this study is to learn whether the early initiation of a specialized and focused type of radiation called stereotactic body radiation therapy (SBRT) will impact the progression of advanced adenoid cystic carcinoma, quality of life, and overall survival.
The name(s) of the study intervention involved in this study is:
* Stereotactic Body Radiation Therapy (SBRT)
Subject must have histologically confirmed adenoid cystic carcinoma (ACC) of any primary site with distant metastases detected clinically or on imaging (biopsy of metastatic disease preferred, but not required)
Cohort 1
One to five detectable sites of metastatic disease at any organ or site (including bone and CNS involvement)
Maximum size of 3 cm for brain lesions.
Cohort 1
Subject who has received systemic therapy for treatment of ACC within 2 weeks of enrollment.
Evidence of need for urgent surgical intervention for metastatic CNS or spine disease.
Cohort 1
Dana-Farber Cancer Institute
Lead sponsor
Adenoid Cystic Carcinoma Research Foundation
Collaborator
Gateway for Cancer Research
Collaborator